Stock Price Quote

NEULAND LABORATORIES LTD.

NSE : NEULANDLABBSE : 524558ISIN CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE6281.30-71.4 (-1.12 %)
PREV CLOSE ( ) 6352.70
OPEN PRICE ( ) 6352.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 419
TODAY'S LOW / HIGH ( )6153.20 6479.75
52 WK LOW / HIGH ( )1698.55 7450
NSE6322.15-37.8 (-0.59 %)
PREV CLOSE( ) 6359.95
OPEN PRICE ( ) 6400.00
BID PRICE (QTY) 6322.15 (190)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 16249
TODAY'S LOW / HIGH( ) 6234.05 6450.00
52 WK LOW / HIGH ( )1695 7318.3
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 07-01 1984
Management Info
Davuluri Rama Mohan Rao - Chairman Davuluri Saharsh Rao - Managing Director
Registered Office

Address 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee Hills,
Hyderabad,
Telangana-500033

Phone 040-67611600 / 67611700

Email neuland@neulandlabs.com

Website www.neulandlabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

04Mar Neuland Laboratories informs about ana
Neuland Laboratories has informed that the Company’s management will be..
26Feb Neuland Laboratories informs about iss
Pursuant to the Regulation 39(3) of the SEBI (Listing Obligations and Di..
01Jan Intimation Of S&P Global ESG Score, 2
As part of our enduring commitment to environmental, social and governan..
13Nov Neuland Laboratories informs about tra
Neuland Laboratories has informed that it enclosed the transcript of the..
20Oct Neuland Laboratories informs about los
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations & Disc..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit807.011631.19
Gross Profit 1037.8 2152.13
Operating Profit 1226.652810.56
Net Sales 3928.2811911.98

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26946.00 (0.74%)
M.Cap ( in Cr)57258.37
Sanofi India (BSE)
peergroup  8118.25 (2.06%)
M.Cap ( in Cr)18696.83
Dr. Reddy's Lab (BSE)
peergroup  6155.15 (1.78%)
M.Cap ( in Cr)102679.14
Divi's Lab (BSE)
peergroup  3436.75 (2.14%)
M.Cap ( in Cr)91234.91
Glaxosmithkline Phar (BSE)
peergroup  1943.10 (3.26%)
M.Cap ( in Cr)32917.29

Shareholding Pattern

NON-INSTITUTION 38.08%
PROMOTERS 32.8%
MUTUAL FUNDS/UTI 1.83%
GOVERNMENT 0.4%
FI/BANKS/INSURANCE 0%
FII 0%

About Neuland Laboratories Ltd.

Neuland Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 6281.3. Its current market capitalisation stands at Rs 8058.84 Cr. In the latest quarter, company has reported Gross Sales of Rs. 11911.98 Cr and Total Income of Rs.12009.46 Cr. The company's management includes Prasad Raghava Menon, Homi Rustam Khusrokhan, Nirmala Murthy, Bharati Rao, Christopher M Cimarusti, Parampally Vasudeva Maiya, Davuluri Saharsh Rao, Davuluri Sucheth Rao, Davuluri Rama Mohan Rao, Sarada Bhamidipati.

It is listed on the BSE with a BSE Code of 524558 , NSE with an NSE Symbol of NEULANDLAB and ISIN of INE794A01010. It's Registered office is at 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee HillsHyderabad-500033, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are KS Aiyar & Co, MSKA & Associates, Walker Chandik & Co LLP, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.